CA3006502A1 - Crystalline forms of quinolone analogs and their salts - Google Patents

Crystalline forms of quinolone analogs and their salts Download PDF

Info

Publication number
CA3006502A1
CA3006502A1 CA3006502A CA3006502A CA3006502A1 CA 3006502 A1 CA3006502 A1 CA 3006502A1 CA 3006502 A CA3006502 A CA 3006502A CA 3006502 A CA3006502 A CA 3006502A CA 3006502 A1 CA3006502 A1 CA 3006502A1
Authority
CA
Canada
Prior art keywords
crystalline form
cancer
compound
exhibits
acid salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3006502A
Other languages
English (en)
French (fr)
Inventor
David M. Ryckman
Iching Grace Yu
Hshiou-Ting Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Priority to CA3255938A priority Critical patent/CA3255938A1/en
Publication of CA3006502A1 publication Critical patent/CA3006502A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3006502A 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts Pending CA3006502A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3255938A CA3255938A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/065443 WO2017105382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3255938A Division CA3255938A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Publications (1)

Publication Number Publication Date
CA3006502A1 true CA3006502A1 (en) 2017-06-22

Family

ID=59057173

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3006502A Pending CA3006502A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts
CA3255938A Pending CA3255938A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3255938A Pending CA3255938A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Country Status (10)

Country Link
EP (2) EP4249072A3 (cg-RX-API-DMAC7.html)
JP (1) JP2018537486A (cg-RX-API-DMAC7.html)
KR (1) KR20180111797A (cg-RX-API-DMAC7.html)
CN (1) CN108699083A (cg-RX-API-DMAC7.html)
AU (2) AU2015417382A1 (cg-RX-API-DMAC7.html)
CA (2) CA3006502A1 (cg-RX-API-DMAC7.html)
ES (1) ES2959536T3 (cg-RX-API-DMAC7.html)
IL (1) IL260004A (cg-RX-API-DMAC7.html)
RU (1) RU2018124599A (cg-RX-API-DMAC7.html)
WO (1) WO2017105382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
EP3752149A4 (en) * 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
US12378245B2 (en) * 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
US20210046071A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Tetracyclic compounds and their salts, compositions, and methods for their use
WO2021030686A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN118005653B (zh) * 2023-04-23 2024-12-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553746A (en) * 2004-09-17 2010-06-25 Cylene Pharmaceuticals Inc Quinolone analogs as cell proliferation inhibitors
EP1926372A2 (en) * 2005-08-19 2008-06-04 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
KR101601332B1 (ko) 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
WO2012123938A1 (en) * 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
EP3074391B1 (en) * 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof

Also Published As

Publication number Publication date
RU2018124599A3 (cg-RX-API-DMAC7.html) 2020-01-16
CA3255938A1 (en) 2025-11-28
EP4249072A3 (en) 2023-10-25
JP2018537486A (ja) 2018-12-20
AU2015417382A1 (en) 2018-06-14
ES2959536T3 (es) 2024-02-26
WO2017105382A1 (en) 2017-06-22
KR20180111797A (ko) 2018-10-11
IL260004A (en) 2018-07-31
EP3394070A1 (en) 2018-10-31
AU2021203085B2 (en) 2023-06-08
EP3394070A4 (en) 2019-05-08
RU2018124599A (ru) 2020-01-16
AU2021203085A1 (en) 2021-06-10
CN108699083A (zh) 2018-10-23
EP3394070B1 (en) 2023-08-02
EP3394070C0 (en) 2023-08-02
EP4249072A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
AU2021203085B2 (en) Crystalline forms of quinolone analogs and their salts
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
US10532988B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
US20220162177A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
JP2015535842A (ja) ニューロトロフィン模倣化合物の結晶形及びその塩
JP2022179783A (ja) キノロン類似体及びその塩の結晶形
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式
HK1212970B (en) Crystalline forms of neurotrophin mimetic compounds and their salts

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201030

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240910

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250704

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226